Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Adhoute

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Gastroenterologie Clinique Et Biologique|March 28, 2006
Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapyXavier Adhoute, Denis Smith, Véronique Vendrely, et al.
Diagnostics (Basel, Switzerland)|April 13, 2023
Radiomics, a Promising New Discipline: Example of Hepatocellular CarcinomaThomas Lévi-Strauss, Bettina Tortorici, Olivier Lopez, et al.
European Journal of Gastroenterology & Hepatology|July 31, 2024
Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life studyXavier Adhoute, Alexia Gonzalez, Thomas Levi-Strauss, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control studyXavier Adhoute, Guillaume Penaranda, Jean Luc Raoul, et al.
Biomedicines|May 27, 2026
Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in PrognosisXavier Adhoute, Constance Chailloux, Feng Xia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 13, 2015
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosisJulien Edeline, Laurence Crouzet, Boris Campillo-Gimenez, et al.
World Journal of Clinical Cases|July 5, 2021
Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts resultsXavier Adhoute, Edouard Larrey, Rodolphe Anty, et al.
Journal of Hepatology|December 3, 2014
Retreatment with TACE: the ABCR SCORE, an aid to the decision-making processXavier Adhoute, Guillaume Penaranda, Sebastien Naude, et al.
World Journal of Gastrointestinal Oncology|September 26, 2022
Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matchingXavier Adhoute, Marie De Matharel, Laurent Mineur, et al.
European Journal of Gastroenterology & Hepatology|May 3, 2019
Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohortXavier Adhoute, Guillaume Pénaranda, Jean-Luc Raoul, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Gastroenterologie Clinique Et Biologique|March 28, 2006
Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapyXavier Adhoute, Denis Smith, Véronique Vendrely, et al.
Diagnostics (Basel, Switzerland)|April 13, 2023
Radiomics, a Promising New Discipline: Example of Hepatocellular CarcinomaThomas Lévi-Strauss, Bettina Tortorici, Olivier Lopez, et al.
European Journal of Gastroenterology & Hepatology|July 31, 2024
Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life studyXavier Adhoute, Alexia Gonzalez, Thomas Levi-Strauss, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control studyXavier Adhoute, Guillaume Penaranda, Jean Luc Raoul, et al.
Biomedicines|May 27, 2026
Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in PrognosisXavier Adhoute, Constance Chailloux, Feng Xia, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 13, 2015
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosisJulien Edeline, Laurence Crouzet, Boris Campillo-Gimenez, et al.
World Journal of Clinical Cases|July 5, 2021
Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts resultsXavier Adhoute, Edouard Larrey, Rodolphe Anty, et al.
Journal of Hepatology|December 3, 2014
Retreatment with TACE: the ABCR SCORE, an aid to the decision-making processXavier Adhoute, Guillaume Penaranda, Sebastien Naude, et al.
World Journal of Gastrointestinal Oncology|September 26, 2022
Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matchingXavier Adhoute, Marie De Matharel, Laurent Mineur, et al.
European Journal of Gastroenterology & Hepatology|May 3, 2019
Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohortXavier Adhoute, Guillaume Pénaranda, Jean-Luc Raoul, et al.
Pageof 7